UiPath (NYSE:PATH) Given New $27.00 Price Target at Evercore ISI

UiPath (NYSE:PATH) had its price target boosted by Evercore ISI from $24.00 to $27.00 in a report issued on Thursday morning, Benzinga reports. Evercore ISI currently has an in-line rating on the healthcare company’s stock.

Several other equities analysts also recently weighed in on PATH. Barclays raised their price target on UiPath from $23.00 to $25.00 and gave the stock an equal weight rating in a research report on Friday. Canaccord Genuity Group upped their price objective on shares of UiPath from $27.00 to $30.00 and gave the company a buy rating in a research note on Friday. Scotiabank began coverage on UiPath in a report on Wednesday, February 21st. They issued a sector perform rating for the company. William Blair initiated coverage on UiPath in a report on Tuesday, January 2nd. They set an outperform rating on the stock. Finally, JPMorgan Chase & Co. upgraded UiPath from a neutral rating to an overweight rating and upped their target price for the company from $22.00 to $28.00 in a research note on Thursday. Nine research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus price target of $27.13.

UiPath Price Performance

UiPath stock traded up $0.32 during trading hours on Thursday, hitting $23.07. The stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. UiPath has a 1-year low of $12.38 and a 1-year high of $27.87. The stock’s fifty day moving average is $23.52 and its two-hundred day moving average is $20.70. The stock has a market capitalization of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97.

Insider Buying and Selling at UiPath

In other news, Director Rich Wong sold 200,000 shares of UiPath stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at $9,928,144.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $22.47, for a total value of $359,520.00. Following the transaction, the chief financial officer now owns 103,505 shares of the company’s stock, valued at $2,325,757.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rich Wong sold 200,000 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $23.12, for a total value of $4,624,000.00. Following the transaction, the director now directly owns 429,418 shares of the company’s stock, valued at $9,928,144.16. The disclosure for this sale can be found here. Insiders have sold 411,000 shares of company stock valued at $9,418,670 over the last three months. 31.03% of the stock is owned by company insiders.

Hedge Funds Weigh In On UiPath

Hedge funds and other institutional investors have recently modified their holdings of the company. Intech Investment Management LLC raised its position in UiPath by 3.1% in the fourth quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock worth $356,000 after acquiring an additional 426 shares in the last quarter. 180 Wealth Advisors LLC raised its holdings in shares of UiPath by 0.3% in the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock worth $4,497,000 after purchasing an additional 492 shares in the last quarter. Bleakley Financial Group LLC lifted its stake in UiPath by 4.9% during the fourth quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after purchasing an additional 598 shares during the last quarter. Simplicity Solutions LLC boosted its holdings in UiPath by 4.9% during the fourth quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after buying an additional 598 shares in the last quarter. Finally, Creative Planning increased its holdings in shares of UiPath by 7.0% in the second quarter. Creative Planning now owns 10,163 shares of the healthcare company’s stock valued at $185,000 after buying an additional 666 shares in the last quarter. Institutional investors and hedge funds own 59.04% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.